​

Fate Therapeutics Ownership | Who Owns Fate Therapeutics?

OverviewForecastRevenueFinancialsChart

Fate Therapeutics Ownership Summary

Fate Therapeutics is owned by 62.35% institutional investors, 1.21% insiders, and 36.44% retail investors. Redmile group is the largest institutional shareholder, holding 10.84% of FATE shares. BB Biotech AG Ord is the top mutual fund, with 4.25% of its assets in Fate Therapeutics shares.

FATE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockFate Therapeutics62.35%1.21%36.44%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Redmile group12.87M10.84%$15.45M
Blackrock10.12M10.01%$33.18M
Blackrock funding, inc. /de10.07M8.48%$12.08M
Boxer capital8.22M8.13%$26.95M
Vanguard group8.97M7.54%$8.82M
Wilshire advisors8.49M7.16%$10.69M
Acadian asset management4.12M3.47%$4.94M
Two sigma investments, lp3.47M2.92%$4.16M
Johnson & johnson3.38M2.84%$4.05M
Aqr capital management3.00M2.53%$3.60M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Wilshire advisors8.49M27.71%$10.69M
Boxer capital8.22M1.42%$26.95M
Redmile group12.87M1.02%$15.45M
Johnson & johnson3.38M0.62%$4.05M
Bruce789.19K0.27%$947.03K
Monaco asset management sam810.00K0.18%$972.00K
Dafna capital management550.00K0.15%$660.00K
Privium fund management b.v.414.31K0.10%$497.17K
Artal group1.03M0.09%$3.39M
Tang capital management1.17M0.07%$1.40M

Top Buyers

HolderShares% AssetsChange
Wilshire advisors8.49M27.71%8.49M
Aqr capital management3.00M0.00%1.84M
Two sigma investments, lp3.47M0.00%1.73M
Ubs group1.82M0.00%1.42M
Acadian asset management4.12M0.01%1.19M

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---5.57M
Bellevue group---4.84M
Deerfield management company, l.p. (series c)---3.56M
Ecor1 capital---3.05M
Suvretta capital management---2.56M

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust653.76K0.00%653.76K$784.51K
Headlands125.71K0.02%125.71K$150.85K
Atom investors lp110.23K0.01%110.23K$138.89K
Algert global106.92K0.00%106.92K$135.00K
Schulhoff100.00K0.05%100.00K$120.00K

Sold Out

HolderChange
Mather group, llc.-5.00
Innealta capital-9.00
Chris bulman-10.00
Turning point benefit group-14.00
Nelson, van denburg & campbell wealth management group-17.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20261587.48%74,066,1332.68%621.70%7850.00%34-35.85%
Dec 31, 202593-34.51%44,014,816-45.32%360.80%31-53.03%31-18.42%
Sep 30, 2025135-3.57%79,628,3630.09%671.49%62-12.68%36-12.20%
Jun 30, 20251384.55%79,496,955-17.58%671.01%7022.81%40-2.44%
Mar 31, 20256-96.23%21,342,655-78.99%180.25%2-97.40%1-97.92%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord4.84M4.25%-
Vanguard US Total Market Shares ETF3.05M2.66%-
Vanguard Total Stock Mkt Idx Inv2.97M2.56%-
iShares Russell 2000 ETF2.56M2.20%21.62K
Vanguard Strategic Equity Inv2.54M2.18%-
SPDR® S&P Biotech ETF2.34M2.06%33.31K
Vanguard Explorer Inv1.27M1.11%-
Vanguard Institutional Extnd Mkt Idx Tr1.18M1.01%75.82K
Fidelity Small Cap Index1.07M0.92%11.75K
iShares Russell 2000 Value ETF903.55K0.78%4.87K

Recent Insider Transactions

DateNameRoleActivityValue
May 20, 2026TAHL CINDY See RemarksSell$48.08K
May 20, 2026Valamehr Bahram President and CEOSell$54.48K
Jan 09, 2026TAHL CINDY See RemarksSell$11.28K
Jan 09, 2026Valamehr Bahram President and CEOSell$5.56K
Aug 04, 2025TAHL CINDY See RemarksSell$9.57K

Insider Transactions Trends

DateBuySell
2026 Q2-2
2026 Q1-2
2025 Q4--
2025 Q3-2
2025 Q2--

FATE Ownership FAQ

Who Owns Fate Therapeutics?

Fate Therapeutics shareholders are primarily institutional investors at 62.35%, followed by 1.21% insiders and 36.44% retail investors. The average institutional ownership in Fate Therapeutics's industry, Biotech Stocks , is 35.75%, which Fate Therapeutics exceeds.

Who owns the most shares of Fate Therapeutics?

Fate Therapeutics’s largest shareholders are Redmile group (12.87M shares, 10.84%), Blackrock (10.12M shares, 10.01%), and Blackrock funding, inc. /de (10.07M shares, 8.48%). Together, they hold 29.32% of Fate Therapeutics’s total shares outstanding.

Does Blackrock own Fate Therapeutics?

Yes, BlackRock owns 10.01% of Fate Therapeutics, totaling 10.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 33.18M$. In the last quarter, BlackRock increased its holdings by 1.02M shares, a 11.17% change.

Who is Fate Therapeutics’s biggest shareholder by percentage of total assets invested?

Wilshire advisors is Fate Therapeutics’s biggest shareholder by percentage of total assets invested, with 27.71% of its assets in 8.49M Fate Therapeutics shares, valued at 10.69M$.

Who is the top mutual fund holder of Fate Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Fate Therapeutics shares, with 4.25% of its total shares outstanding invested in 4.84M Fate Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools